Endotrophin Measured by PRO-C6 as a Prognostic Biomarker for Liver-Related Events in Patients With Advanced Chronic Liver Disease

IF 6.2 2区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Liver International Pub Date : 2026-08-14 DOI:10.1111/liv.70824

Thomas Wiggers, Emilie Toft Skovgaard, Morten Karsdal, Jens Juul Holst, Frederik Christiansen, Andressa de Zawadzki, Diana Julie Leeming, Keyur Patel

{"title":"Endotrophin Measured by PRO-C6 as a Prognostic Biomarker for Liver-Related Events in Patients With Advanced Chronic Liver Disease","authors":"Thomas Wiggers, Emilie Toft Skovgaard, Morten Karsdal, Jens Juul Holst, Frederik Christiansen, Andressa de Zawadzki, Diana Julie Leeming, Keyur Patel","doi":"10.1111/liv.70824","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background & Aims</h3>\n \n <p>Prognostic non-invasive tests for liver-related events in compensated cirrhosis are needed. Endotrophin, a fragment of type VI alpha 3 collagen involved in fibrosis and inflammation, has been associated with adverse outcomes in several chronic diseases. This study examined the association between baseline endotrophin levels, measured by nordicPRO-C6 (PRO-C6), and liver-related events in advanced hepatitis C virus (HCV)-related liver disease.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>nordicPRO-C6 was assessed in baseline serum from 339 patients with advanced liver fibrosis from the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) trial. The prognostic value of PRO-C6 was evaluated.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Baseline serum levels of PRO-C6 were significantly higher in patients with cirrhosis and PRO-C6 was an independent prognostic marker for liver-related events. Each doubling of PRO-C6 was associated with increased hazard of liver-related events in all patients (hazard ratio (HR) = 2.22, 95% confidence interval (CI) 1.57–3.14, <i>p</i> < 0.0001), and in patients with cirrhosis (HR = 1.71, 95% CI 1.14–2.58, <i>p</i> = 0.01).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Endotrophin assessed by PRO-C6 is an independent prognostic marker for liver-related events in patients with advanced liver fibrosis and ongoing inflammation due to HCV, particularly in those with cirrhosis, from the HALT-C trial. PRO-C6 may be useful for risk stratification in end-stage liver disease. However, validation in non–interferon-treated cohorts and across chronic liver diseases of varying etiologies is required to confirm its prognostic value for liver-related events.</p>\n </section>\n </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"46 9","pages":""},"PeriodicalIF":6.2000,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.70824","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver International","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/liv.70824","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background & Aims

Prognostic non-invasive tests for liver-related events in compensated cirrhosis are needed. Endotrophin, a fragment of type VI alpha 3 collagen involved in fibrosis and inflammation, has been associated with adverse outcomes in several chronic diseases. This study examined the association between baseline endotrophin levels, measured by nordicPRO-C6 (PRO-C6), and liver-related events in advanced hepatitis C virus (HCV)-related liver disease.

Methods

nordicPRO-C6 was assessed in baseline serum from 339 patients with advanced liver fibrosis from the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) trial. The prognostic value of PRO-C6 was evaluated.

Results

Baseline serum levels of PRO-C6 were significantly higher in patients with cirrhosis and PRO-C6 was an independent prognostic marker for liver-related events. Each doubling of PRO-C6 was associated with increased hazard of liver-related events in all patients (hazard ratio (HR) = 2.22, 95% confidence interval (CI) 1.57–3.14, p < 0.0001), and in patients with cirrhosis (HR = 1.71, 95% CI 1.14–2.58, p = 0.01).

Conclusion

Endotrophin assessed by PRO-C6 is an independent prognostic marker for liver-related events in patients with advanced liver fibrosis and ongoing inflammation due to HCV, particularly in those with cirrhosis, from the HALT-C trial. PRO-C6 may be useful for risk stratification in end-stage liver disease. However, validation in non–interferon-treated cohorts and across chronic liver diseases of varying etiologies is required to confirm its prognostic value for liver-related events.

查看原文本刊更多论文

内啡肽通过PRO-C6检测作为晚期慢性肝病患者肝脏相关事件的预后生物标志物

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Liver International 医学-胃肠肝病学

CiteScore

13.90

自引率

4.50%

发文量

348

审稿时长

2 months

期刊介绍： Liver International promotes all aspects of the science of hepatology from basic research to applied clinical studies. Providing an international forum for the publication of high-quality original research in hepatology, it is an essential resource for everyone working on normal and abnormal structure and function in the liver and its constituent cells, including clinicians and basic scientists involved in the multi-disciplinary field of hepatology. The journal welcomes articles from all fields of hepatology, which may be published as original articles, brief definitive reports, reviews, mini-reviews, images in hepatology and letters to the Editor.